Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 9, 2019

Primary Completion Date

May 15, 2022

Study Completion Date

May 15, 2022

Conditions
Non-hodgkin Lymphoma,B Cell
Interventions
DRUG

Acalabrutinib

"Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission."

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT04094142 - Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter